Literature DB >> 16941364

Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran.

Mohamad Reza Masjedi1, Parissa Farnia, Setara Sorooch, Majid Valiollah Pooramiri, Seyed Davood Mansoori, Abolhasan Zia Zarifi, Ali Akbarvelayati, Sven Hoffner.   

Abstract

BACKGROUND: Extensively drug-resistant (XDR) tuberculosis (TB) is a cause of concern, because it renders patients untreatable with available drugs. In this study, we documented the existence and transmission of XDR TB among patients with multidrug-resistant TB. These patients were referred to the National Research Institute of Tuberculosis and Lung Diseases (Tehran, Iran) for treatment and diagnosis from 2003 to 2005.
METHODS: The sputum specimens from a total of 2030 patients with TB were digested, examined microscopically for acid-fast bacilli, and inoculated into Lowenstein-Jensen slants by standard procedures. Testing of susceptibility to first-line drugs was performed for 1284 Mycobacterium tuberculosis isolates. Subsequently, the strains that were identified as multidrug-resistant M. tuberculosis (113 isolates) were subjected to susceptibility testing for second-line drugs. Spoligotyping and restriction fragment-length polymorphism were performed for strains that were identified as XDR M. tuberculosis.
RESULTS: A total of 12 (10.9%) of 113 multidrug-resistant M. tuberculosis strains were resistant to all 8 second-line drugs tested and, therefore, were denoted as XDR M. tuberculosis. Retrospective analysis of the cases of XDR TB showed that all of them belonged to 1 of 2 epidemiological clusters, either a single-family cluster (4 cases) or a cluster of close contacts (8 cases). The strains were identified as belonging to the M. tuberculosis superfamilies Haarlem 1 and East African Indian 3.
CONCLUSIONS: The emergence of XDR TB cases in Iran highlights the need to reinforce the Iranian TB policy with regard to control and detection strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941364     DOI: 10.1086/507542

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  43 in total

1.  Structure prediction, molecular simulations of RmlD from Mycobacterium tuberculosis, and interaction studies of Rhodanine derivatives for anti-tuberculosis activity.

Authors:  Harathi N; Sreenivasa Reddy P; Mounica Sura; Jayasimha Rayalu Daddam
Journal:  J Mol Model       Date:  2021-02-06       Impact factor: 1.810

2.  Extensively drug resistant tuberculosis.

Authors:  Stephen D Lawn; Robert Wilkinson
Journal:  BMJ       Date:  2006-09-16

Review 3.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

4.  Mycobacterium tuberculosis Beijing Genotype in Western Iran: Distribution and Drug Resistance.

Authors:  Parviz Mohajeri; Sakineh Moradi; Sara Atashi; Abbas Farahani
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 5.  The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

6.  Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran.

Authors:  M Metanat; B Sharifi-Mood; Sh Shahreki; S H Dawoudi
Journal:  Iran Red Crescent Med J       Date:  2012-01-01       Impact factor: 0.611

7.  DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Stéphanie Matrat; Florence Brossier; Sylvaine Bastian; Delphine Reitter; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada.

Authors:  Paul E Alexander; Prithwish De
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-09       Impact factor: 2.471

9.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

10.  Worldwide emergence of extensively drug-resistant tuberculosis.

Authors:  N Sarita Shah; Abigail Wright; Gill-Han Bai; Lucia Barrera; Fadila Boulahbal; Nuria Martín-Casabona; Francis Drobniewski; Chris Gilpin; Marta Havelková; Rosario Lepe; Richard Lumb; Beverly Metchock; Françoise Portaels; Maria Filomena Rodrigues; Sabine Rüsch-Gerdes; Armand Van Deun; Veronique Vincent; Kayla Laserson; Charles Wells; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.